Purpose of review IDH1/2 mutations occur in up to 70% of low-grade gliomas and secondary glioblastomas. Mutation of these enzymes reduces the wildtype function of the enzyme (conversion of isocitrate to a-ketoglutarate) while conferring a new enzymatic function, the production of D-2-hydroxyglutarate (D-2-HG) from a-ketoglutarate (a-KG). However, it is unclear how these enzymatic changes contribute to tumorigenesis. Here, we discuss the recent studies that demonstrate how IDH1/2 mutation may alter the metabolism and epigenome of gliomas, how these changes may contribute to tumor formation, and opportunities they might provide for molecular targeting.
INTRODUCTION
Gliomas are a collection of nervous system tumors arising from glial cells such as astrocytes and oligodendroglia. The most deadly and aggressive of these gliomas is the grade IV astrocytomas or glioblastoma multiforme (GBM). To better understand the genetic basis of GBM, 22 GBM genomes were sequenced. This study quantified the frequency of previously known mutations (e.g. TP53, EGFRvIII, and PI3KCA) and led to the discovery of acquired mutations in IDH1, which were not previously known or associated with cancer [1] . Subsequent studies discovered mutations in IDH2, the mitochondrial homolog of IDH1 [2] . The role of IDH1/2 mutation in tumorigenesis and tumor maintenance is unclear, but recent findings have implicated altered metabolism, modified epigenetic states, and possible connections between the two as potential tumorigenic mechanisms.
METABOLISM AND CANCER
Associations between metabolism and cancer were first documented in the 1920s by Otto von Warburg, who demonstrated that cancer cells exhibited increased rates of glycolysis and decreased dependence on oxidative phosphorylation, despite the presence of sufficient oxygen [3, 4] . Recently, understanding and therapeutically exploiting altered metabolism in cancer cells has received renewed interest. Oncogenes and tumor suppressors (e.g.
MYC, p53, PI3KCA, etc.) contribute to the regulation of both tumor and normal cell metabolism [5] [6] [7] . However, relatively few mutations in genes encoding metabolic enzymes are known to contribute to oncogenesis. These known mutations include succinate dehydrogenase (SDH), fumarate dehydrogenase, and IDH1/2 [1, 6, 7] . SDH and fumarate dehydrogenase mutations are associated with familial cancer syndromes and lead to enzymatic inactivation with subsequent accumulation of their substrates, succinate and fumarate. Accumulation of these metabolites contributes to tumorigenesis by stabilizing HIF-1a in the presence of sufficient oxygen through inhibition of prolyl hydroxylase domain 2 (PHD2). PHD2 utilizes O 2 and a-ketoglutarate (a-KG) to hydroxylate HIF-1a, leading to its degradation. Inhibition of PHD2 in the presence of sufficient oxygen leads to increased HIF-1a and promotes tumorigenesis through increased glycolysis and angiogenesis [6] [7] [8] [9] [10] .
IDH1/2 MUTATION FREQUENCY
IDH1 mutations occur in up to 12% of all GBMs [1] . GBMs develop de novo (primary) or from lower grade gliomas (secondary). Mutations in IDH1/2 occur in up to 70% of low-grade gliomas and secondary GBMs [2] . IDH1 and IDH2 mutations occur in 16% of acute myelogenous leukemias (AMLs) and up to 33% in AMLs with normal karyotypes [11] , 56% of central and periosteal cartilaginous tumors [12] , and 40% of gliomatosis cerebri cases [13] [14] [15] .
The role of IDH1 or IDH2 mutation as an indicator of progression and survival is not well established. IDH1/2 mutation may result in decreased prognosis for AML [16] [17] [18] and increased prognosis for both low-grade gliomas (65 months for mutant IDH1/2 versus 38 months for wildtype) and secondary GBMs (31 months for mutant IDH1/ 2 versus 15 months for wildtype) [2] . However, IDH1/2 mutant tumors may be recognized earlier than IDH1/2 wildtype tumors, resulting in an apparent, rather than real, association with increased survival.
IDH1 MUTATION AND ENZYMATIC FUNCTION
IDH1 mutations occur at a single amino acid residue, R132 [1, 2] , whereas IDH2 mutations occur at two residues, R140 or R172 (the functional equivalent of R132 in IDH1) [11] . The most common mutation is the R132H IDH1 mutation [2] . IDH1/2 mutations result in two enzymatic changes: decreased wildtype IDH function (oxidative decarboxylation of isocitrate to a-KG with simultaneous reduction of NADP þ ) [19 & ,20,21] and gain of a new enzymatic capability [reduction of a-KG to D-2-hydroxyglutarate (D-2-HG)] with simultaneous oxidation of NADPH [19 & ,20] ( Fig. 1) . Changes in the active site of mutant IDH1/2 enzymes prime the enzyme to produce D-2-HG by increasing its affinity for a-KG [19 & ,20] and shifting the conformation of the enzyme to favor an intermediate transition state [22] .
IDH1/2 MUTATIONS, D-2-HYDROXYGLUTARATE, AND METABOLIC DISORDERS
D-2-HG accumulation is a biochemical hallmark of IDH1/2 mutant tumors. Cells expressing wildtype IDH1/2 have low levels of D-2HG, a byproduct of L-hydroxylysine breakdown, which has no known function within the cell. D-2-HG is removed from the cell through conversion to a-KG by D-2-hydroxyglutarate dehydrogenase. Interestingly, D-2-HG and its stereoisomer L-2-hydroxyglutarate (L-2-HG) accumulate in certain metabolic disorders, D-2 or L-2 hydroxyglutaric aciduria (D-2 or L-2-HGA), respectively [23] [24] [25] [26] .
L-2-HGA results from inactivation of L-2hydroxyglutaric dehydrogenase [25] , whereas D-2-HGA results from inactivation of D-2-hydroxyglutarate dehydrogenase or IDH2 mutations [23, 25, 27, 28] . IDH2 mutations found in D-2-HGA are identical to those documented in gliomas or AML. L-2-HGA patients have been documented to develop gliomas [28] [29] [30] [31] [32] ; however, no cases of glioma have been documented in D-2-HGA patients, despite D-2-HG accumulation [23, [25] [26] [27] . This may suggest that increased D-2-HG levels alone are not sufficient to cause tumorigenesis.
KEY POINTS
IDH1/2 mutations occur frequently and early in the development of low-grade gliomas and secondary GBM.
IDH1/2 mutations produce high levels of D-2-HG, which can inhibit a-KG-dependent enzymes potentially leading to genome-wide epigenetic alterations and altered cellular metabolism.
Mutant IDH1/2 enzymatic activity leads to metabolic alterations including changes in glutamine, N-acetylated amino acid, and fatty acid metabolism.
Targeting the altered metabolism in IDH1/2 mutant gliomas may be a useful therapeutic strategy.
IDH1/2 MUTATIONS AND TUMORIGENESIS
IDH1/2 mutations are significant driver mutations in glioma development as evidenced by computational analyses using Cancer-Specific High-Throughput Analysis of Somatic Mutations (CHASM) [33] . Additionally, IDH1/2 mutations occur first in grade II gliomas and their frequency does not increase with tumor grade, suggesting that these mutations are critical for initial tumor development [2, 34] . How IDH1/2 mutation contributes to the development of cancer is currently under investigation.
Initially, studies suggested that IDH1/2 mutations contribute to tumorigenesis through stabilization of HIF-1a, similar to SDH and fumarate dehydrogenase mutations. The authors suggested a-KG levels were significantly decreased in IDH1/2 mutant cells, leading to inactivation of PHD2 and stabilization of HIF-1a [21] . However, subsequent studies have found that a-KG levels are not significantly altered in IDH1/2 mutant cells, despite increased cellular demand for D-2-HG production ]. Additionally, studies in AML and glioma with IDH1/2 mutations did not detect increased stabilization of HIF-1a [38, 39] . Therefore, although HIF-1a stabilization could contribute to tumorigenesis, other pathways may play a larger role ( Fig. 1) .
In cells harboring IDH1/2 mutations, intracellular D-2-HG levels can reach up to 10 mM [19 & ,20,40]. D-2-HG and a-KG are similar in structure, and recent studies have shown that D-2-HG serves as competitive inhibitor of enzymes that utilize a-KG as a co-factor [38, 41 ] . Crystallographic studies confirm that D-2-HG fits into binding sites for a-KG in dual-specificity histone demethylase KIAA1718 (KDM7A), factor inhibiting hypoxia-inducible factor (FIH), and jumonji domain containing protein 2A (JMJD2A) [38,41 & ]. High intracellular levels of D-2-HG in IDH1/2 mutant tumors are likely sufficient for potent enzymatic inhibition [38] and suggest a possible mechanism by which IDH1/2 mutations contribute to tumorigenesis.
Interestingly, mutant IDH1/2 cases in AML have a characteristic hypermethylated phenotype which may result from inhibition of TET2 by D-2-HG [43 & ]. TET2 catalyzes the conversion of methylcytosine to 5-hydroxymethylcytosine and is mutated in approximately 24% of secondary AMLs. TET2 mutations result in a hypermethylated phenotype similar to that seen in mutant IDH1/2 AMLs, although the two mutations are mutually exclusive [43 & ]. Differentially methylated genes in IDH1 mutant gliomas include processes known to contribute to tumor progression as well as several metabolic pathways ( Table 1 ). In gliomas, a hypermethylated phenotype has also been identified, the glioma-CpG island methylator phenotype (G-CIMP) which correlates tightly with IDH1 mutations. Although 78% of G-CIMP positive tumors possess an IDH1 mutation, no causative link between IDH1/2 mutations and this phenotype has been directly studied [35,44 & ]. ] indentified changes resulting from expression of mutant IDH1/2 or treatment with D-2-HG ( 1) . Some metabolic alterations were found under both conditions; however, approximately half of the observed changes in IDH1/2 mutant expressing cells could not be replicated by treatment with exogenous D-2-HG. Most notably, decreases in glutamate levels and metabolites whose synthesis involves glutamate were not replicated by D-2-HG treatment. Therefore, these changes are a direct result of the enzymatic activity of IDH1/2 mutant enzymes.
IDH1/2 MUTATIONS AND METABOLIC ALTERATIONS
One such metabolic alteration is the reduction of the neuropeptide N-acetyl-aspartyl glutamate (NAAG) and its precursor N-acetylated aspartic acid (NAA) in IDH1/2 mutant cells and tumors by up to 50-fold [36 & ]. NAAG is synthesized from NAA and glutamate by NAAG synthase and functions in glutamatergic pathways of the brain [45] . Reitman et al. found that even when NAA levels are restored, NAAG levels are not fully restored indicating that the glutamate necessary for generation of NAAG may be shuttled for production of a-KG and subsequently D-2-HG. In either case, the consequences of lowered intracellular NAAG levels on tumor formation and maintenance are unknown and warrant further study.
Mutant IDH1/2 produce D-2-HG from glutaminederived a-KG, resulting in increased flux through this pathway [20] . Therefore, cells expressing mutant IDH1/2 may be more dependent upon this pathway for growth and survival. Interestingly, inhibition of a-KG synthesis from glutamine led to a 15-20% decrease in growth for cells expressing mutant IDH1 [37 && ]. To further characterize this growth inhibition, metabolite levels were evaluated following treatment with BPTES, a small molecule inhibitor of glutamine, the first enzyme in the synthesis of a-KG from glutamine. Glutaminase inhibition lowered glutamate and a-KG levels in IDH1 wildtype and mutant cells, but D-2-HG levels were not reduced, indicating the presence of a compensatory mechanism [37 && ].
Changes in the other metabolites following BPTES treatment supported this hypothesis including increases in glycolytic intermediates and decreased levels of TCA cycle intermediates which were seen in both wildtype and mutant IDH1-expressing cells [37 && ]. Consequently, a-KG might be produced or diverted away from the TCA cycle to compensate for inhibition of a-KG produced from glutaminase. Therefore, metabolic inhibition has been shown as a potential approach for selective targeting of IDH1/2 mutant tumors. However, glutaminase inhibition alone is not sufficient as a therapeutic strategy and will require additional components for an effective therapeutic response.
Changes in fatty acid metabolism may also result from IDH1/2 mutant expression. Mutant IDH1-expressing cells exhibit decreased levels of citrate compared with wildtype-expressing IDH1 cells, coupled with increases in acetyl-CoA and triglyceride and phospholipid precursors [36 & ,37 && ]. The combination of decreased citrate and increased lipid precursors may indicate that IDH1 mutant expressing cells shuttle citrate out of the TCA cycle to produce lipids required for cell growth. Increases in fatty acid/lipid synthesis are a common characteristic of many cancers, including gliomas [46] , and it is possible IDH1/2 mutation may contribute to this phenotype. In addition, mutant IDH1 may lead to decreased fatty acid oxidation in two ways: reducing available cofactors for peroxisomal b-oxidation and by decreasing carnitine biosynthesis for mitochondrial fatty acid transport.
Oxidation of a-phytanic acids and b-oxidation of certain fatty acids within peroxisomes requires both NADPH and a-KG, products of wildtype IDH1 activity. IDH1 has been shown to be the sole source of these molecules within the peroxisomes [47] . Mutant IDH1 has decreased the ability to produce NADPH and a-KG, suggesting that mutation of IDH1 may lead to decreased levels of these substrates within peroxisomes and potentially decreased rates of fatty acid oxidation. Chowdhury et al. [38] demonstrated that high levels of D-2-HG can inhibit g-butyrobetaine hydroxylase 1, the last enzymatic step in carnitine biosynthesis. Carnitine is required for activation and transport of fatty acids into the mitochondria to undergo b-oxidation. Consistent with this finding, levels of propionylcarnitine (a carnitine ester which sustains endogenous carnitine pools) were decreased in IDH1/2 mutant and D-2-HG-treated cells [36 & ]. Therefore, IDH1/2 mutations may contribute to tumorigenesis by priming cells for growth by increasing fatty acid synthesis and reducing oxidation of certain fatty acids.
IDH1/2 MUTATIONS AND ANTICANCER METABOLISM BASED THERAPY
The discovery of the IDH1/2 mutation has profound implications for the understanding and treatment of cancer. Elevated D-2-HG levels are characteristic of IDH1/2 mutant tumors and could serve as a biomarker to identify IDH1/2 mutational status or monitor tumor growth or treatment efficacy. Studies in AML have shown that D-2-HG can be detected in serum, and increased D-2-HG levels correlate with IDH1/2 mutational status [19 & ,40] . The use of D-2-HG as a biomarker in gliomas is currently under investigation; however, detection may be technically challenging as the degree of D-2-HG diffusion from solid glial tumors into serum, cerebrospinal fluid, or urine is unknown. Alternatively, D-2-HG can be detected by magnetic resonance spectroscopy (MRS), allowing for noninvasive monitoring of tumor progression or classification of IDH1/2 mutational status [48] .
As it is unclear whether mutant IDH1/2 protein is important for tumor growth or maintenance, targeting the mutant enzymes may not be therapeutically beneficial. Additionally, it is unknown whether changes in methylation status in IDH1/2 mutant cells are reversible by disrupting mutant protein function. The distinct metabolic alterations resulting from IDH1/2 mutations reveal a potential opportunity for therapeutic intervention. Therefore, targeting unique metabolic pathways with IDH1/2 mutant tumors may be an alternative strategy. One potential strategy for the treatment of IDH1/2 mutant tumors is inhibition of a-KG synthesis from glutamine. Studies from our group have demonstrated that inhibition of this pathway can specifically slow the growth of mutant IDH1expressing cells [37 && ]. However, compensatory mechanisms and the mutational background of glioma cells suggest that multiple metabolic components may need to be targeted for the development of a successful therapeutic strategy. Further investigation of the role of IDH1/2 and D-2-HG on the epigenome and the metabolome will likely reveal additional targets. CONCLUSION IDH1/2 mutations are central to the development of a particular subset of gliomas, and further studies could identify targeted treatments for individuals with these mutations. Epigenetic and metabolic alterations in IDH1/2 mutant cells provide clues to the mechanism by which these mutations lead to tumor development and/or maintenance; however, the relative contribution of these changes to each process is currently unknown.
To our knowledge, cell lines and animal models derived from a tumor with a naturally occurring IDH1/2 mutation have not been established. The literature and our experience suggest that IDH1/2 mutant tumors are resistant to cell culture establishment using standard protocols [49] . Therefore, studies of IDH1/2 mutations have been conducted in genetic and metabolic backgrounds which have not developed in concert with an IDH1/2 mutation. Although these efforts have yielded useful insights, cell culture systems and animal tumor models derived from tumors with naturally occurring IDH1/2 mutations need to be developed to better understand the role of mutant IDH1/2 in tumorigenesis and tumor maintenance.
